BrandWikiReturn

Eisai (company)

Eisai Co., Ltd. (エーザイ株式会社) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.[3]

History

Nihon Eisai Co. Ltd. was established in 1941.[4] In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.[5] The American subsidiary of the company, Eisai Inc., was established in 1995.[6]

On November 25, 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer.[7]

Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson.

In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals.[8]

In April 2007, Eisai acquired Exton, Pennsylvania-based Morphotek, a company developing therapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases.

In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for US$3.9 billion.[9] This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio.

In 2009, Eisai received the Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Banzel (rufinamide).[10]

In June 2023, the company suffered from a ransomware attack, causing a shutdown of some of its logistical systems.[11]

Lecanemab, branded as "Leqembi" was approved by the U.S. Food and Drug Administration (FDA) in January 2023 under an Accelerated Approval pathway.[12] The approval was converted into a traditional approval in July 2023.[13]

Locations

Eisai Co., Ltd. is based in Tokyo, Japan, while its American subsidiary, Eisai Inc., is headquartered in Nutley, New Jersey. Eisai Inc. is led by Ivan Cheung as CEO.[14] Eisai maintains medical research headquarters in Nutley as well as at locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute and the Genetics Guided Dementia Discovery (G2D2) institute are based.[15][16]

The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.

Products

Some of the key products that Eisai produces or markets with partners include:

  • Aciphex/Pariet (rabeprazole) - Gastroesophageal reflux disease
  • Actonel (risedronic acid) - Osteoporosis (Japan)
  • Aloxi (palonosetron) - Chemotherapy-induced nausea and vomiting
  • Aricept (donepezil) - Mild to moderate dementia for Alzheimer's Disease patients
  • Banzel/Inovelon (rufinamide) - Seizures related to Lennox-Gastaut Syndrome
  • Belviq (lorcaserin) - Obesity
  • Dayvigo (lemborexant) - Insomnia
  • Fragmin (dalteparin) - Deep vein thrombosis and pulmonary embolism
  • Fycompa (perampanel) - Partial-onset seizures
  • Gliadel Wafer (carmustine) - Treatment for Brain Tumors
  • Halaven (eribulin) - Metastatic breast cancer
  • Iomeron (iomeprol) - Non-ionic contrast medium
  • Lenvima (lenvatinib) - Thyroid Cancer or Kidney Cancer
  • Leqembi (lecanemab) - Alzheimer's disease
  • Methylcobal (methylcobalamin) - Peripheral neuropathy
  • Myonal (eperisone) - Muscle relaxant
  • Selbex (teprenone) - Gastric ulcers and gastritis
  • Zonegran (zonisamide) - Partial-onset seizures

Aricept

Aricept accounted for 40% of Eisai's revenue as of March 2010.[17] The main competitor to Aricept is a generic formulation from Ranbaxy Labs.[17] Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.[17]

See also

  • Biotech and pharmaceutical companies in the New York metropolitan area

External links

References

  1. Eisai Financial Summary 2019 retrieved 21 December 2020^
  2. Eisai Financial Summary 2023 retrieved 2 July 2024^
  3. Components:Nikkei Stock Average Nihon Keizai Shimbun, retrieved February 9, 2015^
  4. Eisai: The First 80 Years | Eisai Co., Ltd^
  5. Claudia Winograd. Eisai (Japan) Encyclopedia of Cancer and Society, SAGE Publications, October 16, 2007, retrieved February 9, 2015^
  6. Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc. Businesswire, retrieved February 9, 2015^
  7. 27 Nov 1996, Page 11 - The Cincinnati Enquirer at Newspapers.com, 1996-11-27, retrieved 2022-06-05^
  8. Eisai Inc. Buys 4 Cancer Drugs From Ligand Pharmaceuticals Inc. For $205 Million BioSpace, retrieved 2020-02-21^
  9. Japan's Eisai to buy MGI Pharma for $3.9 bln Reuters, 2007-12-10, retrieved 2019-11-20^
  10. NORD to Honor Rare Disease Pioneers PR Newswire, May 11, 2009, retrieved February 9, 2015^
  11. Pharmaceutical Giant Eisai Takes Systems Offline Following Ransomware Attack June 8, 2023^
  12. Office of the Commissioner. FDA Grants Accelerated Approval for Alzheimer's Disease Treatment FDA, 2023-01-06, retrieved 2024-07-02^
  13. Office of the Commissioner. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval FDA, 2023-07-07, retrieved 2024-07-02^
  14. Jacob Bell. Eisai gives first glimpse into Alzheimer's drug launch BiopharmaDive, Informa, February 6, 2023, retrieved February 11, 2023^
  15. John Carroll. Eisai launches biotech division in Massachusetts aimed at Alzheimer's, I/O and autoimmune diseases Endpoint News, 15 September 2016, retrieved 4 November 2016^
  16. Eisai Launches Facility to Advance Precision Medicine Genetic Engineering & Biotechnology News, 15 October 2016^
  17. Kanoko Matsuyama. Eisai Aricept Patch for Alzheimer's Isn't Ready for Approval April 25, 2011, retrieved April 25, 2011^